OA13050A - 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. - Google Patents

5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. Download PDF

Info

Publication number
OA13050A
OA13050A OA1200500306A OA1200500306A OA13050A OA 13050 A OA13050 A OA 13050A OA 1200500306 A OA1200500306 A OA 1200500306A OA 1200500306 A OA1200500306 A OA 1200500306A OA 13050 A OA13050 A OA 13050A
Authority
OA
OAPI
Prior art keywords
nmr
400mhz
lrms
pyrazolo
formula
Prior art date
Application number
OA1200500306A
Other languages
English (en)
Inventor
Andrew Simon Bell
David Graham Brown
David Nathan Abraham Fox
Ian Roger Marsh
Andrew Ian Morrell
Michael John Palmer
Carol Ann Winslow
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0327748.0A external-priority patent/GB0327748D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of OA13050A publication Critical patent/OA13050A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
OA1200500306A 2003-04-29 2004-04-22 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension. OA13050A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309780 2003-04-29
GBGB0327748.0A GB0327748D0 (en) 2003-11-28 2003-11-28 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
OA13050A true OA13050A (en) 2006-11-10

Family

ID=33420887

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500306A OA13050A (en) 2003-04-29 2004-04-22 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.

Country Status (32)

Country Link
US (2) US7262192B2 (no)
EP (1) EP1620437B1 (no)
JP (2) JP4015176B2 (no)
KR (1) KR100824193B1 (no)
AR (1) AR044116A1 (no)
AT (1) ATE433978T1 (no)
AU (1) AU2004234158B2 (no)
BR (1) BRPI0409903A (no)
CA (1) CA2523831C (no)
CL (1) CL2004000889A1 (no)
CO (1) CO5640118A2 (no)
CR (1) CR8051A (no)
DE (1) DE602004021585D1 (no)
DK (1) DK1620437T3 (no)
EA (1) EA008596B1 (no)
EC (1) ECSP056130A (no)
ES (1) ES2326119T3 (no)
GE (1) GEP20084329B (no)
HK (1) HK1087108A1 (no)
IS (1) IS8009A (no)
MA (1) MA27771A1 (no)
MX (1) MXPA05011643A (no)
NL (1) NL1026074C2 (no)
NO (1) NO333850B1 (no)
NZ (1) NZ542097A (no)
OA (1) OA13050A (no)
PA (1) PA8601701A1 (no)
PE (1) PE20050462A1 (no)
RS (1) RS20050810A (no)
TW (1) TWI273908B (no)
UY (1) UY28290A1 (no)
WO (1) WO2004096810A1 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ［４，３−ｄ］ピリミジン類
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
BRPI0515478A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP2008517994A (ja) * 2004-10-28 2008-05-29 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 新規医薬品
EP1831216A2 (en) * 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2006111549A1 (de) * 2005-04-21 2006-10-26 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
CN101208093A (zh) * 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
WO2006120552A2 (en) * 2005-05-12 2006-11-16 Pfizer Inc. ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE
SI1881985T1 (sl) * 2005-05-12 2011-03-31 Pfizer Brezvodne kristalinične oblike N-1-(2-etoksietil)-5(N-etil-N-metilamino)-7-(4-metilpriridin-2-il-amino) -1H-pirazolo(4,3-d)pirimidin-3-karbonil"metansulfonamida
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
CA2702518A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh New piperazino-dihydrothienopyrimidine derivatives
WO2009050248A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Substituierte piperidino-dihydrothienopyrimidine
LT2265607T (lt) 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
CN102015719A (zh) * 2008-03-06 2011-04-13 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
WO2009124119A2 (en) * 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
KR101683042B1 (ko) 2008-04-04 2016-12-06 포사이트 비젼4, 인크. 통증 관리 및 시력을 위한 치료 장치
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
NZ590922A (en) * 2008-08-01 2012-09-28 Biocryst Pharm Inc Piperidine derivatives as jak3 inhibitors
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US9498385B2 (en) 2009-10-23 2016-11-22 Nexisvision, Inc. Conformable therapeutic shield for vision and pain
EP2490635B1 (en) 2009-10-23 2017-09-06 Nexisvision, Inc. Corneal denervation for treatment of ocular pain
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
JP5974084B2 (ja) * 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
CA2916885A1 (en) 2013-06-26 2014-12-31 Nexisvision, Inc. Contact lenses for refractive correction
EP3055301B1 (en) 2013-10-07 2019-11-20 Kadmon Corporation, LLC (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases
PT3265126T (pt) 2015-03-03 2021-08-30 Saniona As Formulação combinada de tesofensina e metoprolol
JP6929286B2 (ja) * 2015-12-18 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療用化合物、組成物及びその使用方法
JP7076432B2 (ja) 2016-09-09 2022-05-27 インサイト・コーポレイション Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3621617A1 (en) * 2017-05-12 2020-03-18 Innovus Pharmaceuticals, Inc. Therapeutic methods and compositions
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10758505B2 (en) 2017-12-01 2020-09-01 Innovus Pharmaceuticals, Inc. Therapeutic compositions and methods
US20190167699A1 (en) 2017-12-01 2019-06-06 Innovus Pharmaceuticals, Inc. Prostate function support formula
US10500199B2 (en) 2017-12-01 2019-12-10 Innovus Pharmaceuticals, Inc. Nutritional supplement for increasing cognitive functions
US10864205B2 (en) 2017-12-01 2020-12-15 Innovus Pharmaceuticals, Inc. Nutritional supplement for improving sexual health in men and women
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
PE20210397A1 (es) 2018-02-20 2021-03-02 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
EP4010338A1 (en) 2019-08-06 2022-06-15 Incyte Corporation Solid forms of an hpk1 inhibitor
MX2023000630A (es) * 2020-07-14 2023-03-15 Wuhan Ll Science And Tech Development Co Ltd Inhibidor de rock, y método de preparacion para el mismo y uso del mismo.
WO2024105159A1 (en) 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3951980A (en) 1974-05-09 1976-04-20 Stanford Research Institute 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes
AU516604B2 (en) 1978-04-03 1981-06-11 Yoshida Kogyo K.K. Tiltable roller assembly
ATE171185T1 (de) 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
GB8728483D0 (en) 1987-12-04 1988-01-13 Ciba Geigy Ag Chemical compounds
US5091431A (en) * 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
FR2638745B1 (fr) 1988-11-08 1994-01-14 Synthelabo Derives de ((n-alkylthioalkyl-methylamino)-2 ethyl)-5 benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique
US4994460A (en) 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
JPH03142277A (ja) 1989-10-30 1991-06-18 Fuji Photo Film Co Ltd 記録材料
US5442044A (en) 1991-01-04 1995-08-15 Pfizer Inc. Orally active renin inhibitors
DE69217224T2 (de) 1991-07-03 1997-06-05 Pharmacia & Upjohn Co., Kalamazoo, Mich. Substituierte indole als anti-aids pharmaceutische zubereitungen
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
EP0813534A4 (en) 1995-03-10 1998-06-10 Sanofi Winthrop Inc 6-ARYL PYRAZOLO 3,4-D] PYRIMIDIN-4-ONES, COMPOSITIONS AND METHODS OF USE THEREOF
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CN1227554A (zh) 1996-08-28 1999-09-01 辉瑞大药厂 取代的6,5－杂二环衍生物
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
SK285991B6 (sk) 1997-04-25 2008-01-07 Pfizer Inc. Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
US6184338B1 (en) 1997-08-27 2001-02-06 Fmc Corporation Anionic polymerization initiators containing tertiary amine functionality, their chain extended analogues, and processes for using the same
UA46166C2 (uk) 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
DE19752952A1 (de) 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
CN1134442C (zh) 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
AU5995699A (en) 1998-10-23 2000-05-15 Bunnage, Mark Edward Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
JP2002538208A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
US6465486B1 (en) 1999-03-12 2002-10-15 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl/quinolinyl imidazoles
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
US6506762B1 (en) 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
CN1377355A (zh) 1999-09-30 2002-10-30 纽罗杰有限公司 氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
IL148905A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
AU7547900A (en) 1999-10-11 2001-04-23 Pfizer Inc. 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo(4,3-d)pyrimidin-7-ones as phosphodiesterase inhibitors
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6548509B2 (en) 1999-10-22 2003-04-15 Neurogen Corporation 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
EP1712222A3 (en) 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
GB9930570D0 (en) 1999-12-23 2000-02-16 Pfizer Ltd Therapy
ATE322494T1 (de) 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
US20010047013A1 (en) 2000-03-10 2001-11-29 Fengrui Lang Process for the preparation of arylamines
DE10031584A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
EP1176142A1 (en) 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
WO2002010171A1 (en) 2000-07-28 2002-02-07 Pfizer Limited Crystalline therapeutic agent
YU51701A (sh) 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
HUP0300725A3 (en) 2000-08-11 2005-11-28 Pfizer Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
CA2429605A1 (en) 2000-11-20 2002-05-30 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
DE10058662A1 (de) 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
CN1481244A (zh) 2000-12-19 2004-03-10 Ĭ��ר���ɷ����޹�˾ 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
DE10104095A1 (de) 2001-01-31 2002-08-01 Merck Patent Gmbh Pharmazeutische Formulierung enthaltend Pyrazolo [4,3-d]pyrimidine und Nitrate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
JP2002255932A (ja) 2001-03-01 2002-09-11 Katayama Seiyakushiyo:Kk ３−アルキルアミノアゼチジンの製造方法
US20020127593A1 (en) 2001-03-12 2002-09-12 Regents Of The University Of California Fluorescence assay for DNA modifying enzymes
GB0106631D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6432957B1 (en) 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
EP1490015B1 (en) 2002-03-15 2009-09-23 Wayne State University Novel 2-amino-9-((2-hydroxymethyl) cyclopropylidenemethyl) purines as antiviral agents
DE60237425D1 (de) 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
US7505971B2 (en) 2002-06-28 2009-03-17 Hewlett-Packard Development Company, L.P. Shared drive that provides shared access to editable files in a database
AU2004234158B2 (en) 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension

Also Published As

Publication number Publication date
TWI273908B (en) 2007-02-21
BRPI0409903A (pt) 2006-04-25
EP1620437A1 (en) 2006-02-01
US7262192B2 (en) 2007-08-28
MA27771A1 (fr) 2006-02-01
CR8051A (es) 2006-08-09
WO2004096810A1 (en) 2004-11-11
EA008596B1 (ru) 2007-06-29
EP1620437B1 (en) 2009-06-17
NL1026074C2 (nl) 2005-08-09
US20050043325A1 (en) 2005-02-24
PE20050462A1 (es) 2005-07-19
NL1026074A1 (nl) 2004-11-01
NZ542097A (en) 2008-12-24
GEP20084329B (en) 2008-03-25
DE602004021585D1 (de) 2009-07-30
AR044116A1 (es) 2005-08-24
CA2523831A1 (en) 2004-11-11
UY28290A1 (es) 2004-11-30
JP2006524636A (ja) 2006-11-02
KR20060007405A (ko) 2006-01-24
NO20054404L (no) 2005-11-24
MXPA05011643A (es) 2005-12-15
JP2007217419A (ja) 2007-08-30
RS20050810A (en) 2007-08-03
CL2004000889A1 (es) 2005-03-18
US20070270412A1 (en) 2007-11-22
AU2004234158A1 (en) 2004-11-11
CO5640118A2 (es) 2006-05-31
HK1087108A1 (en) 2006-10-06
NO333850B1 (no) 2013-09-30
NO20054404D0 (no) 2005-09-22
EA200501333A1 (ru) 2006-06-30
DK1620437T3 (da) 2009-08-24
ECSP056130A (es) 2006-03-01
IS8009A (is) 2005-08-31
ES2326119T3 (es) 2009-10-01
TW200503724A (en) 2005-02-01
JP4015176B2 (ja) 2007-11-28
ATE433978T1 (de) 2009-07-15
KR100824193B1 (ko) 2008-04-21
CA2523831C (en) 2008-11-18
AU2004234158B2 (en) 2010-01-28
PA8601701A1 (es) 2004-11-26

Similar Documents

Publication Publication Date Title
OA13050A (en) 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
AU2004290643B2 (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with PDE-5 inhibiting activity
EP1483257B1 (en) Quinazoline compounds useful in therapy
US7713973B2 (en) Kinase inhibitors
CA2585557C (en) Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
AU2011221075B2 (en) Pyrazolopyrimidine compounds and their use as PDE10 inhibitors
EP1689752A1 (en) Pyrazolopyrimidines